VT
REGN icon

Vise Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Vise Technologies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
2,142
+740
+53% +$504K 0.02% 670
2026
Q1 		$1.08M Hold
1,402
– – 0.02% 561
2025
Q4 		$1.08M Buy
1,402
+333
+31% +$226K 0.02% 565
2025
Q3 		$601K Sell
1,069
-1,074
-50% -$607K 0.02% 588
2025
Q2 		$1.12M Buy
+2,143
New +$1.2M 0.05% 407
2024
Q4 		$560K Buy
786
+323
+70% +$271K 0.05% 393
2024
Q3 		$487K Buy
463
+235
+103% +$262K 0.06% 308
2024
Q2 		$240K Buy
228
+16
+8% +$15.5K 0.04% 365
2024
Q1 		$204K Buy
+212
New +$202K 0.04% 361
2022
Q3 		– Sell
-412
Closed -$244K – 337
2022
Q2 		$244K Buy
+412
New +$268K 0.09% 243

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vise Technologies's REGN Position: Q2 2026 in Review

Vise Technologies increased its Regeneron Pharmaceuticals (REGN) stake by 53% in Q2 2026, buying an estimated $504K and bringing the position to 2,142 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #670.

Vise Technologies first reported a position in REGN in Q2 2022 and has held it in 10 quarters since. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Vise Technologies held 2,142 shares of Regeneron Pharmaceuticals worth $1.34M as of Q2 2026.
  • Vise Technologies bought 740 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $504K.
  • Regeneron Pharmaceuticals made up 0.02% of Vise Technologies's portfolio in Q2 2026, its #670 holding.
  • Vise Technologies first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.